Patent intelligence · US
US 6211239
Method for treating or preventing breast cancer or leukemia using 6-[3-[1-adamantyl]-4-hydroxyphenyl]-2-naphthalene carboxylic acid (AHPN)
Method for treating or preventing breast cancer or leukemia using 6-[3-[1-adamantyl]-4-hydroxyphenyl]-2-naphthalene carboxylic acid (AHPN)
Patent details — US 6211239
- Jurisdiction
- US
- Status
- expired
- Grant date
- Apr 3, 2001
- Expiration
- Mar 29, 2021
- Claims
- 4
- CPC classes
- A61K, A61K31/192
Quick answer
US 6211239 (Method for treating or preventing breast cancer or leukemia using 6-[3-[1-adamantyl]-4-hydroxyphenyl]-2-naphthalene carboxylic acid (AHPN)) is held by Centre International de Recherches Dermatalogiques Galderma (C.I.R.D.) Galderma. Status: expired. Granted Apr 3, 2001. Expires Mar 29, 2021 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Grant date
- Expiration
- Claims
- 4
- CPC classes
- A61K, A61K31/192
More from Centre International de Recherches Dermatalogiques Galderma (C.I.R.D.) Galderma
Related pharmaceutical patents in our USPTO index.
-
US 12208123
Compositions and methods for the treatment of skin conditions
granted -
US 6759396
Compositions based on a synergistic mixture of at least one VDR ligand and a retinoid
expired -
US 6593359
Use of a RAR-&ggr;-specific agonist ligand for increasing the rate of apoptosis
expired -
US 6515021
Bicyclic aromatic compounds
expired -
US 6506796
Use of a RAR-&ggr;-specific agonist ligand for increasing the rate of apoptosis
expired -
US 6368608
Polyaromatic propynyl compounds and pharmaceutical/cosmetic compositions comprised thereof
expired -
US 6326510
Bi-aromatic compounds, compositions containing them and uses
expired -
US 6313162
Propynyl or dienyl biaromatic compounds
expired
Related coverage
Frequently asked questions
What is US patent 6211239?
US 6211239 (Method for treating or preventing breast cancer or leukemia using 6-[3-[1-adamantyl]-4-hydroxyphenyl]-2-naphthalene carboxylic acid (AHPN)) is held by Centre International de Recherches Dermatalogiques Galderma (C.I.R.D.) Galderma. Status: expired. Granted Apr 3, 2001. Expires Mar 29, 2021 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 6211239?
Centre International de Recherches Dermatalogiques Galderma (C.I.R.D.) Galderma is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 30 pharmaceutical patents for this assignee.
When does US 6211239 expire?
Our index shows an expiration date of Mar 29, 2021 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.